Zimmer Biomet to Present at Morgan Stanley Healthcare Conference on September 8, 2025.

Zimmer Biomet Holdings will present at the Annual Morgan Stanley Healthcare Conference on September 8, 2025. The management team will discuss the company's progress and future outlook. A live webcast of the presentation can be accessed on Zimmer Biomet's Investor Relations website. The company has a comprehensive portfolio designed to maximize mobility and improve health.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has announced its participation in the upcoming Annual Morgan Stanley Healthcare Conference, scheduled for Monday, September 8, 2025, at 8:30 a.m. ET. The company's management team will deliver a presentation, which can be accessed via a live webcast on Zimmer Biomet's Investor Relations website. The presentation will also be available for replay after the conference concludes.

In the second quarter of 2025, Zimmer Biomet reported $2.08 billion in sales and an operating margin of nearly $300 million, outperforming revenue expectations but falling short of earnings per share (EPS) projections [2]. The company's U.S. hips and knees franchises were notable performers, contributing to 2.8% organic growth despite headwinds such as delayed international orders and tariff impacts. The company raised its full-year organic revenue growth outlook to 3.5%–4.5% (excluding Paragon 28) and adjusted its EPS guidance to $8.10–$8.30, citing stronger operational efficiency and less tariff drag than expected.

A key highlight of the presentation is expected to be Zimmer Biomet's pending acquisition of Monogram Technologies, maker of the first robot to complete a fully autonomous surgery with Monogram implants. The acquisition is seen as a significant move to enhance Zimmer Biomet's robotics capabilities and complement its ROSA platform. This strategic move positions Zimmer Biomet as a leader in surgical ecosystems, spanning advanced digital tools, ASCs (Ambulatory Surgical Centers), and robotics.

Chairman, President, and CEO Ivan Tornos emphasized the company's resilience and focus on high-growth segments. The company's CFO Suketu Upadhyay underscored continued investment in ASCs and robotics, noting that early adoption and commercial expansion will drive "second half acceleration." Despite softer market signals in June, Tornos maintained that the overall market remains healthy and above pre-COVID levels, with sustained demand expected into 2026.

Zimmer Biomet's presentation is set to provide insights into its strategic direction, focusing on core reconstructive markets, growth in robotics, and the expansion of ASCs. The company aims to lead the next wave of orthopedic innovation, with fully autonomous robotics becoming a key differentiator. Investors and industry professionals are encouraged to tune in to the presentation for a comprehensive update on Zimmer Biomet's progress and future outlook.

References:
[1] https://www.stocktitan.net/news/ZBH/zimmer-biomet-to-present-at-the-annual-morgan-stanley-healthcare-xy3uv4s2231i.html
[2] https://ryortho.com/2025/08/zimmer-biomet-delivers-solid-q2-all-eyes-on-robotics-and-monogram/